Back to top

Analyst Blog

On Mar 25, Zacks Investment Research upgraded Teleflex Incorporated (TFX - Snapshot Report) to a Zacks Rank #2 (Buy) from a Zacks Rank #3 (Hold).

Why the Upgrade?

Teleflex has been witnessing rising estimate revisions over the past 60 days with two upward estimate revisions and no downward revision for 2014. The upward estimate revisions led to a 0.5% rise in Zacks Consensus Estimate to $5.52 per share for the year over the same time frame. Moreover, the company delivered positive earnings surprises in all of the last four quarters with an average beat of 8.6%.

This leading global provider of medical devices for critical care and surgery reported impressive fourth-quarter 2013 results and a promising 2014 guidance on Feb 21, 2014, subsequent to which its shares adopted an upward trend. Shares of Teleflex also hit a new 52-week high of $106.22 in mid-day trading on Mar 21.

Teleflex recently announced receiving the 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its restated Indications for Use of the EZ-IO Vascular Access System. The Vascular Access System has been developed by Vidacare Corporation, acquired by Teleflex in December last year.

For the fourth quarter of 2013, Teleflex posted adjusted earnings of $1.36 per share (up 18.6% year over year) which comfortably beat the Zacks Consensus Estimate of $1.27. Net revenue grew 7.5% to $450.5 million, exceeding the Zacks Consensus Estimate of $436 million.

Teleflex is using mergers & acquisitions (M&A) to build out a diverse critical care business. The acquisitions of LMA International in Oct 2012 and Vidacare Corporation in Dec 2013 made significant contributions to revenue growth in the fourth quarter.

Furthermore, Teleflex reported a 50 basis points improvement in its fourth quarter operating margin of 7.8% due to management’s focus on operating cost improvement.

For 2014, Teleflex provided revenue growth estimate in the range of 6–8% and adjusted earnings per share guidance in the range of $5.35–$5.55. The current Zacks Consensus Estimate of $5.49 lies within the guided range.

An encouraging guidance, increased M&A activity and stronger operating leverage represent a potential upside for Teleflex going forward.

Other Stocks to Consider

Some other stocks worth reckoning in the medical instruments industry are Cynosure, Inc. (CYNO - Snapshot Report), Syneron Medical Ltd. (ELOS - Snapshot Report) and Delcath Systems, Inc. . All the three stocks carry a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BANCO DO BR… BDORY 14.55 +4.30%
ERBA DIAGNO… ERB 3.69 +3.94%
AIR INDUSTR… AIRI 9.90 +3.23%
WEATHERFORD… WFT 23.63 +3.05%
EQT MIDSTRE… EQM 97.81 +3.03%